[Editor's note: A version of this article appeared previously in our sister publication, Pink Sheet.]
The US Food and Drug Administration may be headed for a second straight year of cuts to its non-user fee funding, a move that could hamper its ability to handle increasing salary obligations, complete a major
Key Takeaways
-
The House subcommittee bill would cut the FDA's non-user fee funding for the second consecutive year.
-
Advocates caution that the appropriations process is just beginning, but argued the agency deserves an increase rather than a cut